Industry Genentech pays Alector $100 million for Parkinson’s drug rights Fierce Biotech reported that Genentech will pay Alector $100 million upfront for exclusive rights to a preclinical drug candidate for Parkinson’s disease. Reported by 2 outlets · Tuesday, October 6, 2026 Photo: Public domain, U.S. Navy Medicine The original reports on this story are listed below. Reporting on this story Fierce Biotech Genentech pays Alector $100M for preclinical Parkinson’s prospect (opens in a new tab)
Research Three scientists win Nobel for discoveries behind optogenetics The Nobel recognized work that lets researchers use light to switch nerve cells on or off and study brain circuits. Reported by 10 outlets
Infectious disease Health agencies monitor suspected plague case after Russian lab worker dies WHO said the worker’s cause of death has not been confirmed and the risk to the general population appears low. Reported by 6 outlets
Outbreaks New York declares measles emergency as Pennsylvania outbreak tops 1,000 cases New York declared an emergency with 108 measles cases and expanded who can administer vaccines, as Pennsylvania reported 1,004 cases. Reported by 3 outlets